Story perspectives

CVS Urges Gilead to Cut Yeztugo's $28,000 Price

10/25/2025

49 11

Summary

Story summary

CVS Caremark's chief medical officer Dr. Michelle Gourdine urged Gilead Sciences to lower Yeztugo's U.S. price, which is $28,000, noting generic versions cost $40 in other countries.
CVS has not included Yeztugo in its recommended therapies due to the high cost and instead advocates a generic-first approach to improve affordability and health outcomes.
Gilead's pricing strategy has raised concerns about equitable access to this significant medical advancement.

1 of 1

Story summary

CVS Caremark's chief medical officer Dr. Michelle Gourdine urged Gilead Sciences to lower Yeztugo's U.S. price, which is $28,000, noting generic versions cost $40 in other countries.
CVS has not included Yeztugo in its recommended therapies due to the high cost and instead advocates a generic-first approach to improve affordability and health outcomes.
Gilead's pricing strategy has raised concerns about equitable access to this significant medical advancement.